Application of specific lectin combination in construction of test tool for identifying adenocarcinoma in lung cancer based on saliva glycoprotein carbohydrate chains

Abstract

The invention provides an application of specific lectin combination in construction of a test tool for identifying adenocarcinoma (ADC) in lung cancer based on saliva glycoprotein carbohydrate chains, wherein the specific lectin combination is selected from four kinds of lectin of PHA-E+L, STL, WFA and Jacalin. Compared with lung squamous cell carcinoma (SCC) and small cell lung cancer (SCLC) samples, an adenocarcinoma (ADC) sample shows significantly different expression of the specific lectin combination. Moreover, a model is also established and shown in the specification; if the detectionvalue is greater than or equal to 0.697, it is indicated that the subject to which a saliva sample belongs to is an ADC patient, or otherwise, the subject to which the saliva sample belongs is otherlung disease patients (SCC, SCLC or COPD patients).

Description

technical field [0001] The invention relates to the application of a specific lectin combination to construct a test tool for identifying adenocarcinoma in lung cancer based on sialoglycoprotein sugar chain. Background technique [0002] Worldwide, one in five men and one in six women will develop cancer in their lifetime, and one in eight men and One in 1 women dies from the disease. The report estimates the incidence and mortality of 36 cancers in 185 countries around the world. According to the report, new cases will reach 18.1 million this year, and the death toll will reach 9.6 million. Four years ago, the number of new cases and deaths was 14.1 million and 8.2 million, respectively. Lung cancer is one of the leading causes of death in both men and women, with the highest incidence of lung cancer in women in regions such as North America, Northern Europe and Western Europe, as well as in countries such as China, Australia and New Zealand. [0003] Primary bronchial ...

AI Technical Summary

Problems solved by technology

[0005] Although great progress has been made in the treatment of lung cancer in recent years, overall, the prognosis of lung cancer is still very unsatisfactory. The 5-year survival rates of non-small cell lung cancer and small cell lung cancer are only 14% and 4%, respectively. %

The main reason for this situation is that the onset of lung cancer is hidden, and there are usually no obvious symptoms in the early stage. Most lung cancer patients are already in the advanced stage when they are diagnosed, and they lose the chance of surgical cure.

Images